2024 | Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study
| BREAST CANCER RESEARCH |
2024 | Clinical Relevance of <i>TP53</i> Mutation and Its Characteristics in Breast Cancer with Long-Term Follow-Up Date
| CANCERS |
2024 | Age and Late Recurrence in Young Patients With ER-Positive, <i>ERBB2</i>-Negative Breast Cancer
| JAMA NETWORK OPEN |
2024 | Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h+HER2-breast cancer: a retrospective analysis
| BREAST CANCER RESEARCH |
2024 | Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative
| NPJ BREAST CANCER |
2024 | Dural Metastasis in Breast Cancer: MRI-Based Morphological Subtypes and Their Clinical Implications
| CANCER RESEARCH AND TREATMENT |
2024 | De novo versus recurrent metastatic breast cancer affects the extent of brain metastases | JOURNAL OF NEURO-ONCOLOGY |
2024 | Micrometastases in axillary lymph nodes in breast cancer, post-neoadjuvant systemic therapy
| BREAST CANCER RESEARCH |
2024 | Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
| SCIENTIFIC REPORTS |
2024 | Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Human Epidermal Growth Factor 2-Positive/Triple-Negative Breast Cancer Patients With Excellent Response | JOURNAL OF BREAST CANCER |
2024 | Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates
| BREAST CANCER RESEARCH |
2024 | Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study
| BREAST CANCER RESEARCH |
2024 | Tumor-Infiltrating Lymphocyte Level Consistently Correlates with Lower Stiffness Measured by Shear-Wave Elastography: Subtype-Specific Analysis of Its Implication in Breast Cancer
| CANCERS |
2024 | Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
| YONSEI MEDICAL JOURNAL |
2024 | Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial
| JOURNAL OF BREAST CANCER |
2024 | Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade
| CANCERS |
2024 | Prediction of a Multi-Gene Assay (Oncotype DX and Mammaprint) Recurrence Risk Group Using Machine Learning in Estrogen Receptor-Positive, HER2-Negative Breast Cancer-The BRAIN Study
| CANCERS |
2024 | Elasticity Values as a Predictive Modality for Response to Neoadjuvant Chemotherapy in Breast Cancer
| CANCERS |
2024 | BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer
| CELL DEATH DISCOVERY |
2023 | YAP1 Expression in HR+HER2- Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
| CANCERS |
2023 | Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery
| SCIENTIFIC REPORTS |
2023 | Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review
| JOURNAL OF BREAST CANCER |
2023 | Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
| JAMA NETWORK OPEN |
2023 | Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer
| YONSEI MEDICAL JOURNAL |
2023 | Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1) | BREAST CANCER |
2023 | Radiation dose-event relationship after intraoperative radiotherapy as a boost in patients with breast cancer
| FRONTIERS IN ONCOLOGY |
2023 | Optimal treatment strategy for hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer patients with 1-2 suspicious axillary lymph node metastases on breast magnetic resonance imaging: upfront surgery vs. neoadjuvant chemotherapy
| FRONTIERS IN ONCOLOGY |
2023 | Resolution of Nonmass Enhancement Extension to the Nipple at Breast MRI after Neoadjuvant Chemotherapy: Pathologic Response and Feasibility for Nipple-sparing Mastectomy | RADIOLOGY |
2023 | Complications Including Capsular Contracture in Direct-to-Implant Breast Reconstruction With Textured Anatomical Versus Smooth Round Implants: A Single Center Retrospective Analysis
| JOURNAL OF BREAST CANCER |
2023 | Knowledge, attitudes, and behaviors toward fertility preservation in patients with breast cancer: A cross-sectional survey of physicians
| FRONTIERS IN ONCOLOGY |
2023 | Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
| CANCER MEDICINE |
2022 | Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
| JOURNAL OF BREAST CANCER |
2022 | 18F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence
| SCIENTIFIC REPORTS |
2022 | Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor-Positive, ERBB2-Negative Breast Cancer
| JAMA NETWORK OPEN |
2022 | Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer
| CANCERS |
2022 | Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
| DIAGNOSTICS |
2022 | CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer | SCIENCE IMMUNOLOGY |
2022 | Effects of Single Nucleotide Polymorphisms and Mediterranean Diet in Overweight or Obese Postmenopausal Women With Breast Cancer Receiving Adjuvant Hormone Therapy: A Pilot Randomized Controlled Trial
| FRONTIERS IN NUTRITION |
2022 | RT-induced dynamic changes in the lymphocyte-to-monocyte ratio in patients with breast cancer indicate poor prognosis | BREAST CANCER RESEARCH AND TREATMENT |
2022 | SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
| CANCERS |
2022 | Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
| NPJ BREAST CANCER |
2022 | Survival Outcomes of Patients With Breast Cancer Diagnosed Using Vacuum-Assisted Biopsy: A Nationwide Study From the Korean Breast Cancer Society
| JOURNAL OF BREAST CANCER |
2022 | Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
| NPJ BREAST CANCER |
2022 | Added value of abbreviated breast magnetic resonance imaging for assessing suspicious microcalcification on screening mammography-a prospective study | EUROPEAN RADIOLOGY |
2021 | The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy
| CANCERS |
2021 | Relationship of the standard uptake value of 18 F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm
| SCIENTIFIC REPORTS |
2021 | Diagnostic Accuracy of Nonmass Enhancement at Breast MRI in Predicting Tumor Involvement of the Nipple: A Prospective Study in a Single Institution | RADIOLOGY |
2021 | PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
| SCIENTIFIC REPORTS |
2021 | Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer
| INTERNATIONAL JOURNAL OF CANCER |
2021 | Metastasis Risk Assessment Using BAG2 Expression by Cancer-Associated Fibroblast and Tumor Cells in Patients with Breast Cancer
| CANCERS |